FDA approves adjuvant cemiplimab for high-risk cutaneous squamous cell carcinoma
On October 8, 2025, the U.S. Food and Drug Administration (FDA) approved adjuvant cemiplimab, a PD-1 inhibitor, for post-surgical high-risk cutaneous squamous cell carcinoma (CSCC).1 CSCC accounts for...
View ArticleFDA approves first-line combination maintenance therapy lurbinectedin and...
On October 2, 2025, the U.S. Food and Drug Administration (FDA) approved lurbinectedin and atezolizumab for adult patients with extensive-stage small cell lung cancer (ES-SCLC) in the frontline...
View ArticleNovel delivery systems for bladder cancer: advancing intravesical and...
Bladder cancer remains a major therapeutic challenge, with high recurrence rates and a need for repeated interventions that impact patient quality of life. Standard treatments for high-risk non-muscle...
View ArticleFDA approves subcutaneous pembrolizumab for solid tumors
On September 19, 2025, the U.S. Food and Drug Administration (FDA) granted approval to subcutaneous (SC) administration of pembrolizumab, together with berahyaluronidase alfa (MK-3475A; from now on...
View ArticleFDA approves gemcitabine intravesical system for BCG-unresponsive non-muscle...
On September 9 2025, the U.S Food and Drug Administration (FDA) approved gemcitabine intravesical system (formerly TAR-200) for adults with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle...
View ArticleFDA approves 3-month leuprolide mesylate in advanced prostate cancer
On August 29 2025, the U.S Food and Drug Administration (FDA) approved a three-month depot formulation of leuprolide mesylate, a gonadotropin-releasing hormone (GnRH) agonist, in patients with...
View ArticleInnovations in precision medicine for biliary tract cancers
New targets, new therapies, overcoming resistance, and IO combination approaches Biliary tract cancers (BTCs), encompassing intrahepatic and extrahepatic cholangiocarcinoma as well as gallbladder...
View ArticleFDA approves sunvozertinib for non-small cell lung cancer with EGFR Ex20Ins
On July 2 2025, the U.S Food and Drug Administration (FDA) approved sunvozertinib, an oral, irreversible mutant EGFR-selective tyrosine kinase inhibitor (TKI) for adults with non-small cell lung...
View ArticleKEYNOTE‑689: perioperative pembrolizumab redefines curative-intent treatment...
The Phase III KEYNOTE‑689 trial (NCT03765918) presented compelling results at ASCO 2025 and AACR 2025, confirming that adding pembrolizumab to standard perioperative therapy significantly improves...
View ArticleClik here to view.
Advancing colorectal cancer screening: new technologies and lower age...
Colorectal cancer (CRC) remains a formidable healthcare challenge despite being one of the most preventable cancers. While about 90% of cases are preventable1, CRC disease continues as the second...
View ArticleFDA approves taletrectinib for ROS1-positive advanced non-small cell lung cancer
On June 11, 2025, the U.S. Food and Drug Administration (FDA) has approved taletrectinib, an oral next-generation ROS1-selective tyrosine kinase inhibitor (TKI), for adults with ROS1-positive advanced...
View ArticleClik here to view.
Novel therapeutic combination strategies for advanced melanoma
Introduction Melanoma, a highly aggressive form of skin cancer, has seen significant advancements in treatment with the advent of immune checkpoint inhibitors (ICIs) targeting the programmed cell...
View ArticleFDA grants accelerated approval to telisotuzumab vedotin for advanced NSCLC...
The U.S. Food and Drug Administration has granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis, AbbVie Inc.), marking a significant milestone in the treatment of advanced non-small cell...
View ArticleTrastuzumab deruxtecan gains FDA Approval: expanding treatment options for...
On January 27, 2025, the U.S. Food and Drug Administration (FDA) recently approved trastuzumab deruxtecan (T-DXd) for patients with human epidermal growth factor receptor 2 (HER2)-low and...
View ArticleFDA approves sotorasib with panitumumab for KRAS G12C-mutated metastatic...
On January 16, 2025, the U.S. Food and Drug Administration (FDA) granted approval to the combination of sotorasib, a KRAS inhibitor, and panitumumab, an anti-EGFR antibody, for adult patients with...
View ArticleFDA approves perioperative and post-surgical adjuvant nivolumab for...
On October 3rd 2024, the U.S. Food and Drug Administration (FDA) recent approved nivolumab as a perioperative therapy for patients with resectable stage IIA to IIIB non-small cell lung cancer...
View ArticleFDA approves pembrolizumab combination with chemotherapy as first-line...
The Food and Drug Administration (FDA) recently approved the combination of pembrolizumab with pemetrexed and platinum chemotherapy as a first-line treatment for patients with unresectable advanced or...
View ArticleNADINA trial establishes new standard in stage III melanoma treatment:...
The NADINA trial (NCT04949113) marks a significant milestone in melanoma treatment, representing the first Phase III trial to compare neoadjuvant immunotherapy with the standard adjuvant approach and...
View ArticleFDA approves osimertinib with platinum-based chemotherapy in EGFR-mutated NSCLC
Lung cancer accounts for approximately one in ten cases of cancer, with non-small cell lung cancer (NSCLC) accounting for a substantial portion of cases.1 Targeted therapies have played a significant...
View ArticleFDA approves pembrolizumab in combination with chemoradiotherapy for cervical...
Cervical cancer remains a significant global health concern, particularly affecting women in resource-limited settings. According to the World Health Organization (WHO), cervical cancer is the fourth...
View Article
![[-100%] Commodity Intelligence – (Android Apps)](http://play-lh.googleusercontent.com/j67-qJvmnn4xnVlYVZ9ZhtZUJIgwjKekJGoKQT6D1KHcWGZxtQaFroummEvwV17na7tyh1pGbbeWCRdWtTKqeg=w950-h950)
